Cancer immunotherapies
by design™
iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.
At iTeos, we specialize in targeted immunotherapies for people living with cancer.
We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.
Our two clinical stage programs, EOS-448 and Inupadenant, were designed with the aim of having best-in-class properties. We are moving rapidly into late stage clinical trials to explore the full potential of our science.
Our pipeline
Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
EOS-448
+ dostarlimab | 1L NSCLC PDL1high
Phase 2, planned
+ dostarlimab | HNSCC
Phase 2, active
+ dostarlimab + CD96 | Advanced Malignancies
Phase 1, active
+ dostarlimab + Inupadenant | Advanced Malignancies
Phase 1, planned
+ Inupadenant | Advanced Malignancies
Phase 2, active
Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma
Phase 2, active
Inupadenant
Monotherapy | High Biomarker
Phase 2, active
+ pembrolizumab | PD-1 Resistant Melanoma
Phase 2, active
+ chemotherapy | 2L Chemo-naive NSCLC
Phase 2, active
EOS-984
IND Enabling Studies
Preclinical, active
Studies with dark backgrounds are active. Studies with light backgrounds are planned.
There has never been a better time to work at iTeos.
As a leading clinical-stage biotech, our innovative science-driven work is fascinating and potentially lifesaving.
Whether it is working in our laboratory or in our offices, you will help people live healthier lives. You will find yourself on the forefront of science, within a high-tech environment where no two days are the same.
Latest press releases
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
– Began enrolling patients with head and neck squamous cell carcinoma in Phase 2 trial expansion evaluating anti-TIGIT monoclonal antibody,…
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company…
